Related Experiment Video
Updated: Nov 18, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Complement, a Therapeutic Target in Diabetic Kidney Disease
Kelly Budge1, Sergio Dellepiane1, Samuel Mon-Wei Yu1
1Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Insights
Current diabetic kidney disease treatments are limited. Targeting the complement system, a part of immunity, shows promise for halting DKD progression by reducing inflammation.
Area of Science:
- Immunology
- Nephrology
- Pharmacology
Background:
- Diabetic kidney disease (DKD) treatments are insufficient despite advances in understanding its pathology.
- The complement system, crucial for immunity, can cause disease when overactivated, leading to inflammation.
- Evidence indicates complement system activation plays a role in DKD pathogenesis.
Purpose of the Study:
- To review diabetic kidney disease (DKD) and the complement system's role in kidney diseases.
- To explore the potential of complement inhibition as a novel therapeutic strategy for DKD.
- To discuss the benefits of targeting complement pathways in DKD patients.
Main Methods:
- Literature review of DKD pathophysiology.
- Analysis of the complement system's involvement in diabetic and non-diabetic kidney conditions.
- Evaluation of complement inhibition strategies based on existing drug data and clinical outcomes in other kidney diseases.
Main Results:
- Dysregulated complement activation is implicated in DKD.
- Complement inhibition has proven effective in other kidney diseases.
- Targeting the complement system offers a potential new therapeutic avenue for DKD.
Conclusions:
- Complement inhibition represents a promising therapeutic approach for diabetic kidney disease.
- Further research into complement targeting therapies could significantly benefit DKD patients.
- Modulating the complement system may halt or slow the progression of DKD.
Abstract:
Currently available treatments of diabetic kidney disease (DKD) remain limited despite improved understanding of DKD pathophysiology. The complement system is a central part of innate immunity, but its dysregulated activation is detrimental and results in systemic diseases with overt inflammation. Growing evidence suggests complement activation in DKD. With existent drugs and clinical success of treating other kidney diseases, complement inhibition has emerged as a potential novel therapy to halt the progression of DKD. This article will review DKD, the complement system's role in diabetic and non-diabetic disease, and the potential benefits of complement targeting therapies especially for DKD patients.
More Related Videos
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
16:26Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Chronic Kidney Disease II: Clinical Manifestations
Kidney Transplant I: Introduction
Heart Failure Drugs: Diuretics